Karunya Kandimalla to Blood-Brain Barrier
This is a "connection" page, showing publications Karunya Kandimalla has written about Blood-Brain Barrier.
Connection Strength
7.160
-
Wang Z, Veerareddy V, Tang X, Thompson KJ, Krishnan S, Kalari KR, Kandimalla KK. QSP Modeling Shows Pathological Synergism Between Insulin Resistance and Amyloid-Beta Exposure in Upregulating VCAM1 Expression at the BBB Endothelium. CPT Pharmacometrics Syst Pharmacol. 2025 Mar; 14(3):561-571.
Score: 0.802
-
Salian VS, Tang X, Thompson KJ, Curan GL, Lowe VJ, Li L, Kalari KR, Kandimalla KK. Molecular Mechanisms Underlying Amyloid Beta Peptide Mediated Upregulation of Vascular Cell Adhesion Molecule-1 in Alzheimer Disease. J Pharmacol Exp Ther. 2024 Nov 19; 391(3):430-440.
Score: 0.796
-
Wang Z, Zhong R, Curran GL, Min P, Lowe VJ, Li L, Kandimalla KK. High-Density Lipoprotein Mimetic Peptide 4F Reduces Toxic Amyloid-Beta Exposure to the Blood-Brain Barrier Endothelium in Alzheimer's Disease Transgenic Mice. Mol Pharm. 2024 Nov 04; 21(11):5661-5671.
Score: 0.790
-
Zhou AL, Swaminathan SK, Salian VS, Wang L, Curran GL, Min HK, Lowe VJ, Kandimalla KK. Insulin Signaling Differentially Regulates the Trafficking of Insulin and Amyloid Beta Peptides at the Blood-Brain Barrier. Mol Pharm. 2024 May 06; 21(5):2176-2186.
Score: 0.764
-
Zhou AL, Sharda N, Sarma VV, Ahlschwede KM, Curran GL, Tang X, Poduslo JF, Kalari KR, Lowe VJ, Kandimalla KK. Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-? Peptides and Insulin. J Alzheimers Dis. 2022; 85(3):1031-1044.
Score: 0.652
-
Wang Z, Sharda N, Curran GL, Li L, Lowe VJ, Kandimalla KK. Semimechanistic Population Pharmacokinetic Modeling to Investigate Amyloid Beta Trafficking and Accumulation at the BBB Endothelium. Mol Pharm. 2021 11 01; 18(11):4148-4161.
Score: 0.643
-
Sharda N, Ahlschwede KM, Curran GL, Lowe VJ, Kandimalla KK. Distinct Uptake Kinetics of Alzheimer Disease Amyloid-? 40 and 42 at the Blood-Brain Barrier Endothelium. J Pharmacol Exp Ther. 2021 03; 376(3):482-490.
Score: 0.605
-
Zhou AL, Swaminathan SK, Curran GL, Poduslo JF, Lowe VJ, Li L, Kandimalla KK. Apolipoprotein A-I Crosses the Blood-Brain Barrier through Clathrin-Independent and Cholesterol-Mediated Endocytosis. J Pharmacol Exp Ther. 2019 06; 369(3):481-488.
Score: 0.539
-
Agyare EK, Leonard SR, Curran GL, Yu CC, Lowe VJ, Paravastu AK, Poduslo JF, Kandimalla KK. Traffic jam at the blood-brain barrier promotes greater accumulation of Alzheimer's disease amyloid-? proteins in the cerebral vasculature. Mol Pharm. 2013 May 06; 10(5):1557-65.
Score: 0.353
-
Agyare EK, Curran GL, Ramakrishnan M, Yu CC, Poduslo JF, Kandimalla KK. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res. 2008 Nov; 25(11):2674-84.
Score: 0.258
-
Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther. 2005 Jun; 313(3):1370-8.
Score: 0.203
-
Wang Z, Sharda N, Omtri RS, Li L, Kandimalla KK. Amyloid-Beta Peptides 40 and 42 Employ Distinct Molecular Pathways for Cell Entry and Intracellular Transit at the Blood-Brain Barrier Endothelium. Mol Pharmacol. 2023 11; 104(5):203-213.
Score: 0.182
-
Gali CC, Fanaee-Danesh E, Zandl-Lang M, Albrecher NM, Tam-Amersdorfer C, Stracke A, Sachdev V, Reichmann F, Sun Y, Avdili A, Reiter M, Kratky D, Holzer P, Lass A, Kandimalla KK, Panzenboeck U. Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-? in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice. Mol Cell Neurosci. 2019 09; 99:103390.
Score: 0.137
-
Ahlschwede KM, Curran GL, Rosenberg JT, Grant SC, Sarkar G, Jenkins RB, Ramakrishnan S, Poduslo JF, Kandimalla KK. Cationic carrier peptide enhances cerebrovascular targeting of nanoparticles in Alzheimer's disease brain. Nanomedicine. 2019 02; 16:258-266.
Score: 0.130
-
Swaminathan SK, Ahlschwede KM, Sarma V, Curran GL, Omtri RS, Decklever T, Lowe VJ, Poduslo JF, Kandimalla KK. Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain. J Cereb Blood Flow Metab. 2018 05; 38(5):904-918.
Score: 0.119
-
Agyare EK, Jaruszewski KM, Curran GL, Rosenberg JT, Grant SC, Lowe VJ, Ramakrishnan S, Paravastu AK, Poduslo JF, Kandimalla KK. Engineering theranostic nanovehicles capable of targeting cerebrovascular amyloid deposits. J Control Release. 2014 Jul 10; 185:121-9.
Score: 0.095
-
Jaruszewski KM, Ramakrishnan S, Poduslo JF, Kandimalla KK. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine. 2012 Feb; 8(2):250-60.
Score: 0.079
-
Poduslo JF, Ramakrishnan M, Holasek SS, Ramirez-Alvarado M, Kandimalla KK, Gilles EJ, Curran GL, Wengenack TM. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem. 2007 Jul; 102(2):420-33.
Score: 0.015